It didn’t take long for Larry Kestelman to dunk on a set of mutinous plans to force him out of the National Basketball ...
For those who believe in the accuracy of Scripture, this latest archaeological find is a powerful reminder: the Bible’s history is real.
The name Jared Novelly isn’t likely to chime with readers of this column, unless it suddenly emerges that they bear a passion ...
"Excellent attention to detail" isn't just a selling point during a job interview. "When someone truly cares, they listen and ...
Q4 2024 Earnings Call Transcript March 17, 2025 Protalix BioTherapeutics, Inc. beats earnings expectations. Reported EPS is $0.09, expectations were $0.07. Operator: Good morning, ladies and gentlemen ...
Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025.
Discover Protalix BioTherapeutics' Q4 2024 earnings insights, including record revenues, pipeline advancements, and future growth prospects.
Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback